Windlas Biotech Ltd (WINDLAS) — shareholding pattern, promoter holding, financials and share price
About Windlas Biotech Ltd (WINDLAS)
Windlas Biotech Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as WINDLAS and on the BSE under scrip code 543329. Its ISIN is INE0H5O01029.
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics. [1]
Windlas Biotech Limited is a vertically integrated Indian pharmaceutical company focused on formulation development, commercial GMP manufacturing and marketing across three strategic verticals: Generic Formulations CDMO, Trade Generics & Institutional sales, and Exports, with five WHO‑GMP plants in Dehradun and a recently commissioned injectable facility driving diversification across dosage forms.
Windlas delivered record revenues for the twelfth consecutive quarter: 9MFY26 revenue of Rs 666 crore and Q3FY26 revenue of Rs 233 crore, reflecting YoY growth of 19% and 20% respectively, driven by CDMO strength, rising injectable contributions and Plant‑2 extension benefiting utilization and volumes across core businesses.
Listed peers in Pharmaceuticals: NGL Fine Chem Ltd, Sakar Healthcare Ltd, Hester Biosciences Ltd, Amrutanjan Health Care Ltd, Jagsonpal Pharmaceuticals Ltd, Shukra Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹830 a share on 10 Jul 2026, Windlas Biotech Ltd (WINDLAS) was valued at a price-to-earnings ratio of 25.78x against an industry P/E of 36.41x and a price-to-book of 2.95x on a book value of ₹281.47 per share as of Mar 2026. Solomo computes return on equity of 11.44% and return on capital employed of 14.9% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 25.78x
- Industry P/E
- 36.41x
- P/B
- 2.95x
- EPS (TTM)
- ₹32.2
- Book value / share
- ₹281.47
- ROE
- 11.44%
- ROCE
- 14.9%
- ROA
- 7.32%
- Debt / equity
- 0.06x
- Dividend yield
- 0.7%
- EBITDA margin
- 13.56%
- 52-week range
- ₹699.35 – ₹1,095
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Windlas Biotech Ltd (WINDLAS) reported revenue of ₹904 crore, net profit of ₹66 crore and earnings per share of ₹31.49. That compares with revenue of ₹760 crore and net profit of ₹61 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹238 crore and net profit ₹16 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 466 | 513 | 631 | 760 | 904 |
| Net profit (₹ cr) | 38 | 43 | 58 | 61 | 66 |
| EPS (₹) | 17.48 | 20.04 | 27.98 | 29.1 | 31.49 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 16.15% | 20.78% | 18.98% |
| Profit growth | 33.67% | 15.95% | 8.97% |
| Stock price CAGR | - | 38% | -9% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 63.31% of Windlas Biotech Ltd (WINDLAS) (up 1.41 pp QoQ), foreign institutional investors (FII) hold 2.04% and domestic institutional investors (DII) hold 9.84%. Market capitalisation was ₹1,713 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2021.
Largest disclosed public shareholders in Jun 2026: Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund 3.42%, Mncl Capital Compounder Fund 2 1.7%, Bandhan Small Cap Fund 1.43%, Ajay Kumar Aggarwal 1.21%, Perpetuity Health To Wealth (H2w) Rising Fund 1.11%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 63.31% | - | 2.04% | 9.84% | 36.69% |
| Mar 2026 | 61.9% | - | 0.6% | 11.81% | 38.1% |
| Dec 2025 | 61.99% | - | 0.93% | 11.44% | 38.01% |
| Sep 2025 | 61.99% | - | 1.11% | 11.43% | 38.01% |
| Jun 2025 | 62.34% | - | 1.44% | 11.21% | 37.66% |
| Mar 2025 | 62.34% | - | 1.52% | 10.89% | 37.66% |
| Dec 2024 | 62.51% | - | 1.55% | 10.26% | 37.49% |
| Sep 2024 | 62.51% | - | 2% | 9.58% | 37.49% |